Krystal Biotech holder plans sale of 12,500 shares

Krystal Biotech common stockholder plans to sell 12,500 shares under Rule 144.

Rhea-AI Filing Summary

Krystal Biotech common stockholder plans to sell 12,500 shares under Rule 144. The shares are to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $3,458,250 and 28,997,519 shares of Krystal Biotech common stock shown as outstanding.

The seller acquired these 12,500 shares on 02/09/2026 through the exercise of a stock option originally granted on 02/28/2022, paying cash for the shares. The notice includes a representation that the seller is not aware of any undisclosed material adverse information about Krystal Biotech’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for KRYS disclose about planned share sales?

The Form 144 shows a planned sale of 12,500 Krystal Biotech common shares. These shares are to be sold on NASDAQ through Fidelity Brokerage Services, with an aggregate market value of $3,458,250 and 28,997,519 common shares listed as outstanding.

How many Krystal Biotech (KRYS) shares are covered by this Rule 144 notice?

The notice covers 12,500 shares of Krystal Biotech common stock. These shares were acquired by exercising a stock option and are proposed for sale on NASDAQ, with the filing listing an aggregate market value of $3,458,250 for this planned transaction.

How and when were the KRYS shares in this Form 144 acquired?

The 12,500 Krystal Biotech shares were acquired on 02/09/2026 by exercising a stock option. The option was originally granted on 02/28/2022 by the issuer, and the filing indicates the exercise was paid for in cash at the time of acquisition.

Which broker and exchange are involved in the KRYS Form 144 sale?

The filing lists Fidelity Brokerage Services LLC as the broker handling the transaction. The proposed sale of 12,500 Krystal Biotech common shares is to occur on the NASDAQ exchange, consistent with the broker and exchange information disclosed in the document.

What aggregate market value is associated with the KRYS shares in this filing?

The 12,500 Krystal Biotech common shares are assigned an aggregate market value of $3,458,250. This value appears in the securities information table, alongside the share count, broker details, NASDAQ listing, and total common shares outstanding for the issuer.

What does the Form 144 representation say about inside information on KRYS?

The person for whose account the securities are to be sold represents that they do not know any material adverse information about Krystal Biotech’s current or prospective operations that has not been publicly disclosed, as part of the standard Rule 144 notice language.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 04:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801385
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Krystal Biotech, Inc.
SEC File Number	001-38210
Address of Issuer	2100 WHARTON STREET SUITE 701 PITTSBURGH PENNSYLVANIA 15203
Phone	(412) 586-5830
Name of Person for Whose Account the Securities are To Be Sold	ROMANO KATHRYN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	12500	3458250.00	28997519	02/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/09/2026	Option Granted - 02/28/2022	Issuer			12500	02/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/06/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Kathryn Romano
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)